Accentus Medical Shortlisted for OBN UK Medtech Development Award

04 September 2015

Accentus Medical, a leading developer of advanced surface modifications and coating technologies, is pleased to announce it has been shortlisted as a top three finalist for the Best New UK Medtech Development Programme in the OBN 2015 Awards.

Accentus Medical’s shortlisting reflects a highly successful year, which has seen peer review publication of data evidencing clinical performance of its innovative Agluna® silver ion based antimicrobial surface technology through its commercial partnership with Stanmore Implants in the limb salvage sector. The company has also made significant progress towards adoption of Agluna® within the wider orthopaedic device market through its partnership with Zimmer Biomet, a global market leader in musculo-skeletal care, and is also now beginning to commercialise Agluna® into other medical device sectors such as cardiac implantable electronic devices, dental and cranioplasty devices.

The winners in each of eleven award categories will be announced at the OBN Annual Awards Dinner taking place on Thursday 1 October 2015 at the Ashmolean Museum, Oxford. The event will be attended by senior executives and influential players from the most innovative and dynamic biotech and medtech companies in the OBN network.

Dr Philip Agg, CEO, said: “We are very proud to be nominated as a finalist in the category of Best New UK Medtech Development Programme. This is recognition of the hard work and entrepreneurship of our employees and their high-quality research and development endeavours within a demanding industry sector. We are looking forward to continuing the exciting journey of building Accentus Medical as a high growth UK company supplying innovative, world leading technologies to an increasing portfolio of customers within the global medical device market.”


For further information, please contact:
Lynne Trowbridge
T: +44 (0)20 7457 2861

About Agluna®
Agluna® harnesses the anti-microbial properties of silver ions in preventing device related infection. The technology is an electrochemical process involving high voltage anodisation of the titanium implant in phosphoric acid, followed by incorporation of silver ions from an aqueous solution. Agluna® is protected by several patent families registered in major global territories.

About Accentus Medical
Accentus Medical is a global leader in delivery of innovative, silver-based anti-microbial surface treatments and biocompatible coatings on implantable medical devices. The company combines a long history of expertise in surface technologies, with dedicated research and development of new technologies for the medical device industry. Based at the historic Harwell Oxford campus, Accentus Medical has provided expertise in surface technologies to the orthopaedic device industry since the 1970s, serving major orthopaedic and medical device manufacturers worldwide.

The company has three principal technology platforms:
• Agluna® silver anti-microbial surface treatment for prevention and control of post-operative infection,
• Acusure® plasma spray coating for improving biocompatibility and durability of implants,
• Acusure Ag® plasma spray coating incorporating antimicrobial silver ions

These technologies are supplied to customers at Accentus Medical’s ISO13485:2012 and ISO9001:2008 accredited facility. Accentus Medical is also very well known for the medical device testing programmes offered by its in-house test laboratories. Manufacturers have been utilising test results provided by the company for many years as part of device homologation files all over the world.

For further information, please visit:

About OBN
OBN is the membership organisation supporting and bringing together the UK’s emerging life sciences companies, corporate partners and investors. The OBN Annual Awards celebrate outstanding achievements within the UK life sciences sector over the preceding year.

Download PDF

Contact Us

T: +44 (0)1235 434 320
F: +44 (0)1235 434 329